Abstract:Abstract Background The CRISPR-Cas12a (formerly Cpf1) system is a versatile gene-editing tool with properties distinct from the broadly used Cas9 system. Features such as recognition of T-rich protospacer-adjacent motif (PAM) and generation of sticky breaks, as well as amenability for multiplex editing in a single crRNA and lower off-target nuclease activity, broaden the targeting scope of available tools and enable more accurate genome editing. However, the widespread use of the nuclease for gene editing, especially in clinical applications, is hindered by insufficient activity and specificity despite previous efforts to improve the system. Currently reported Cas12a variants achieve high activity with a compromise of specificity. Here, we used structure-guided protein engineering to improve both editing efficiency and targeting accuracy of Acidaminococcus sp. Cas12a ( As Cas12a) and Lachnospiraceae bacterium Cas12a ( Lb Cas12a). Results We created new As Cas12a variant termed “ As Cas12a-Plus” with increased activity (1.5~2.0-fold improvement) and specificity (reducing off-targets from 29 to 23 and specificity index increased from 92% to 94% with 33 sgRNAs), and this property was retained in multiplex editing and transcriptional activation. When used to disrupt the oncogenic BRAF V600E mutant, As Cas12a-Plus showed less off-target activity while maintaining comparable editing efficiency and BRAF V600E cancer cell killing. By introducing the corresponding substitutions into Lb Cas12a, we also generated Lb Cas12a-Plus (activity improved ~1.1-fold and off-targets decreased from 20 to 12 while specificity index increased from 78% to 89% with 15 sgRNAs), suggesting this strategy may be generally applicable across Cas12a orthologs. We compared Cas12a-Plus, other variants described in this study, and the reported enCas12a-HF, enCas12a, and Cas12a-ultra, and found that Cas12a-Plus outperformed other variants with a good balance for enhanced activity and improved specificity. Conclusions Our discoveries provide alternative As Cas12a and Lb Cas12a variants with high specificity and activity, which expand the gene-editing toolbox and can be more suitable for clinical applications.

PAM-flexible Engineered FnCas9 variants for robust and ultra-precise genome editing and diagnostics

PAM-Flexible Genome Editing with an Engineered Chimeric Cas9.

A Cas9 with PAM recognition for adenine dinucleotides

Functional Non-Homologous End Joining Patterns Triggered by CRISPR/Cas9 in Human Cells.

FokI-RYdCas9 Mediates Nearly PAM-Less and High-Precise Gene Editing in Human Cells

An Engineered ScCas9 with Broad PAM Range and High Specificity and Activity.

Rational Design of Enhanced Nme2Cas9 and Nme2 Cas9 Nucleases and Base Editors

Engineered CRISPR-Cas9 nuclease with expanded targeting space

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity

FrCas9 is a CRISPR/Cas9 system with high editing efficiency and fidelity

Engineered Campylobacter jejuni Cas9 variant with enhanced activity and broader targeting range

Engineered CRISPR-Cas9 nucleases with altered PAM specificities

Expansion of the prime editing modality with Cas9 from Francisella novicida

Versatile and robust genome editing with Streptococcus thermophilus CRISPR1-Cas9

Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing

Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants

A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo

Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease

Two Compact Cas9 Ortholog-Based Cytosine Base Editors Expand the DNA Targeting Scope and Applications In Vitro and In Vivo

In-depth assessment of the PAM compatibility and editing activities of Cas9 variants